Novel Agents for Adult ALL: Is it Curtains for Chemo?

Tyrosine kinase inhibitors and novel agents like bi-specific T-cell engager and antibody drug conjugates have diminished the need for chemotherapy in adults with acute lymphoblastic leukemia (ALL).

Related Keywords

Germany ,Georgia ,United States ,Dana Farber Cancer Institute ,Massachusetts ,Philadelphia ,Pennsylvania ,Atlanta ,Frankfurt ,Brandenburg ,Boston ,University Of Pennsylvania ,Utah ,American ,German ,Bryand Huber ,Noellev Frey ,Marlise Luskin ,American Society Of Hematology ,Goethe University Hospital In Frankfurt ,American Society Of Hematology Annual Meeting Exposition ,Novartis ,Goethe University Hospital ,Intermountain Healthcare ,Salt Lake City ,American Society ,Hematology Annual Meeting ,Presented December ,Acute Leukemia ,Chemotherapy ,Hematology ,Leukemia ,Combination Drug Therapy ,Rug Therapy Combination ,Biologic Therapy ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Ar T ,Drug Development ,Antibody Drug Conjugates Adcs ,Bone Marrow ,Hodgkins Lymphoma ,Remission ,Transplantation ,Transplant ,Tyrosi ,